{"id":"W4402565608","doi":"10.1016/j.annonc.2024.08.2310","title":"LBA67 Cabozantinib (C) plus atezolizumab (A) versus 2nd novel hormonal therapy (NHT) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final overall survival (OS) results of the phase III, randomized, CONTACT-02 study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta; Centre Hospitalier de l’Université de Montréal","funders":"Movember Foundation","keywords":"Medicine; Atezolizumab; Cabozantinib; Prostate cancer; Oncology; Hormonal therapy; Internal medicine; Randomized controlled trial; Cancer; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007464678,0.001094054,0.00163673,0.000370459,0.0002493564,0.0009143187,0.0007271549,0.000858626,0.00445188],"category_scores_gemma":[0.000826219,0.0003987143,0.001289587,0.0003894843,0.0006506453,0.0007804303,0.0003021136,0.00219269,0.0007342555],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000772366,"about_ca_system_score_gemma":0.00101072,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002675069,"about_ca_topic_score_gemma":0.008611675,"domain_scores_codex":[0.9997297,0.0001391771,0.00001265015,0.00004356903,0.00002039041,0.00005455772],"domain_scores_gemma":[0.9995279,0.0001069695,0.00009880505,0.00003043141,0.00002091361,0.0002149687],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9527494,0.006663601,0.002157123,0.0004136183,0.0009288811,0.0000476453,0.00005914468,0.000847301,0.004105709,0.0001114002,0.00143012,0.03048609],"study_design_scores_gemma":[0.8157865,0.166662,0.01216981,0.0000591427,0.001233915,0.0001222749,0.00009137672,0.001224995,0.000957666,0.0001998234,0.001462326,0.00003007981],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939558,0.002905621,0.0001485088,0.0003423326,0.0001683716,0.0002818853,0.0006959374,0.00007312981,0.001428395],"genre_scores_gemma":[0.994052,0.001587097,0.0004137962,0.0005124178,0.0002050656,0.0002299548,0.0009520213,0.0000174045,0.002030201],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00445188,"threshold_uncertainty_score":0.014893,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1515018057328011,"score_gpt":0.4396081740076889,"score_spread":0.2881063682748878,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}